文献速递血栓与止血

静脉血栓栓塞症患者围手术期桥接抗凝:一项基于登记处的队列研究

Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study.
PubMed 文献 · J Thromb Haemost · 2020-06-25

本研究纳入2010至2018年间六家医疗体系中因手术暂时停用华法林的静脉血栓栓塞症患者789例,共1529次手术。依据2012年美国胸科医师学会指南评估桥接抗凝使用情况,结果显示高危患者桥接使用率高于低中危患者,但低危患者存在过度使用、高危患者存在使用不足,不良事件罕见且两组无统计学差异。

要点

  • 高危患者桥接抗凝使用率57.9%(99/171),高于中危47.8%(515/1078)和低危47.86%(134/280)。
  • 高危与低中危患者桥接使用差异在未调整分析(P=0.013)和患者水平聚类调整分析(P=0.031)中均显著。
  • 研究期间高危和低危患者对美国胸科医师学会指南的依从性无变化(OR 0.98/年,95%CI 0.91-1.05)。

核心结论

  • 低危静脉血栓栓塞症患者中华法林桥接抗凝存在过度使用,高危患者中存在使用不足。
  • 不良事件罕见,且两个治疗组之间无统计学差异。

研究设计与样本

  • 基于登记处的队列研究,纳入2010至2018年间六家医疗体系中因手术暂时停用华法林的静脉血栓栓塞症患者789例,共1529次手术(中位数2次,四分位距1-4)。
  • 依据2012年美国胸科医师学会指南,按复发性静脉血栓栓塞症风险评估围手术期桥接抗凝的使用。
  • 采用logistic回归调整每位患者多次手术,评估复发性静脉血栓栓塞症风险和30天结局(出血、血栓栓塞、急诊就诊)。

主要发现

  • 未调整的桥接抗凝使用率在高危患者中为57.9%(99/171),高于中危患者的47.8%(515/1078)和低危患者的47.86%(134/280)。
  • 高危患者桥接抗凝使用率高于低危或中危患者,未调整分析P=0.013,患者水平聚类调整分析P=0.031。
  • 研究期间高危和低危患者对美国胸科医师学会指南的依从性无变化(OR 0.98/年,95%CI 0.91-1.05)。
  • 不良事件罕见,且两个治疗组之间无统计学差异。

关键数值与推荐

  • 高危患者桥接抗凝使用率57.9%(99/171),中危47.8%(515/1078),低危47.86%(134/280)。
  • 高危与低中危患者桥接使用差异:未调整分析P=0.013,患者水平聚类调整分析P=0.031。
  • 指南依从性随时间变化:OR 0.98/年,95%CI 0.91-1.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Use of bridging anticoagulation increases a patient's bleeding risk without clear evidence of thrombotic prevention among warfarin-treated patients with atrial fibrillation. Contemporary use of bridging anticoagulation among warfarin-treated patients with venous thromboembolism (VTE) has not been studied. METHODS: We identified warfarin-treated patients with VTE who temporarily stopped warfarin for a surgical procedure between 2010 and 2018 at six health systems. Using the 2012 American College of Chest Physicians guideline, we assessed use of periprocedural bridging anticoagulation based on recurrent VTE risk. Recurrent VTE risk and 30-day outcomes (bleeding, thromboembolism, emergency department visit) were each assessed using logistic regression adjusted for multiple procedures per patient. RESULTS: During the study period, 789 warfarin-treated patients with VTE underwent 1529 procedures (median, 2; interquartile range, 1-4). Unadjusted use of bridging anticoagulation was more common in patients at high risk for VTE recurrence (99/171, 57.9%) than for patients at moderate (515/1078, 47.8%) or low risk of recurrence (134/280, 47.86%). Bridging anticoagulation use was higher in high-risk patients compared with low- or moderate-risk patients in both unadjusted (P = .013) and patient-level cluster-adjusted analyses (P = .031). Adherence to American College of Chest Physicians guidelines in high- and low-risk patients did not change during the study period (odds ratio, 0.98 per year; 95% confidence interval, 0.91-1.05). Adverse events were rare and not statistically different between the two treatment groups. CONCLUSIONS: Bridging anticoagulation was commonly overused among low-risk patients and underused among high-risk patients treated with warfarin for VTE. Adverse events were rare and not different between the two treatment groups.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Barnes GD, Li Y, Gu X, et al. Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study. J Thromb Haemost. 2020. PMID: 32428998. doi:10.1111/jth.14903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。